2003
DOI: 10.1161/01.hyp.0000074426.71392.d8
|View full text |Cite
|
Sign up to set email alerts
|

Endothelin-1 and Vascular Tone in Subjects With Atherogenic Risk Factors

Abstract: Abstract-Endothelin-1 (ET-1) is a potent vasoconstrictor that increases vascular tone in the resistance vessels of subjects with hypertension. It is unclear whether endogenous ET-1 affects resistance-vessel function equally in patients with other cardiovascular risk factors. Vasoconstriction to ET-1 is mediated principally via the endothelin-A (ET A ) receptor on vascular smooth muscle cells. Accordingly, we used an ET A -specific antagonist, BQ-123, to test the hypothesis that endogenous ET-1 increases vascul… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

3
30
0
1

Year Published

2005
2005
2024
2024

Publication Types

Select...
5
3
1

Relationship

0
9

Authors

Journals

citations
Cited by 54 publications
(34 citation statements)
references
References 57 publications
3
30
0
1
Order By: Relevance
“…On the other hand, endothelin antagonism has been reported to markedly improve NO-production/bioavailability, resulting in enhancement of the vasodilating effect in most types of atherosclerotic diseases. [18][19][20][21][22][23][24][25][26] This has also been reported in patients with PAH due to collagen diseases. 27,28) The vasodilating effect of sildenafil definitely requires cGMP-production and is also thought to be synergistically exerted in well-ventilated lung areas possessing an intact NO-cGMP system where NO is more abundant than in lung areas with ventilation disorders and/or an impaired NO-cGMP system.…”
Section: Pretreatment With Bosentan Decreases [Sil] and [Des]supporting
confidence: 59%
“…On the other hand, endothelin antagonism has been reported to markedly improve NO-production/bioavailability, resulting in enhancement of the vasodilating effect in most types of atherosclerotic diseases. [18][19][20][21][22][23][24][25][26] This has also been reported in patients with PAH due to collagen diseases. 27,28) The vasodilating effect of sildenafil definitely requires cGMP-production and is also thought to be synergistically exerted in well-ventilated lung areas possessing an intact NO-cGMP system where NO is more abundant than in lung areas with ventilation disorders and/or an impaired NO-cGMP system.…”
Section: Pretreatment With Bosentan Decreases [Sil] and [Des]supporting
confidence: 59%
“…Atherogenic lipid abnormalities clearly cause endothelial dysfunction. 4 A dysfunctional endothelium, possibly through impaired nitric oxide production and activity, as well as alterations in endothelin-1 and endothelin A and B receptor expression, 24 cannot respond to changes in intravascular conditions to constrict and dilate as needed. This vasodysregulation could lead to an inability or difficulty in vasodilatation to appropriate stimuli and eventually to increased resting BP.…”
Section: Discussionmentioning
confidence: 99%
“…[6][7][8][9] Endogenous ET-1, which acts via EDNRA, increases resistance-vessel tone in subjects with hypertension to a level greater than that in smokers and in subjects with hypercholesterolemia. 10 Plasma ET-1 concentrations can be reduced by resistance training and aerobic exercise. 11 Pulse wave velocity (PWV) is generally recognized as a surrogate marker for atherosclerosis.…”
Section: Introductionmentioning
confidence: 99%